208 related articles for article (PubMed ID: 11289159)
1. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Roth W; Isenmann S; Nakamura M; Platten M; Wick W; Kleihues P; Bähr M; Ohgaki H; Ashkenazi A; Weller M
Cancer Res; 2001 Mar; 61(6):2759-65. PubMed ID: 11289159
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.
Wu YY; Chang YC; Hsu TL; Hsieh SL; Lai MZ
J Biol Chem; 2004 Oct; 279(42):44211-8. PubMed ID: 15475369
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.
Hwang SL; Lin CL; Cheng CY; Lin FA; Lieu AS; Howng SL; Lee KS
Kaohsiung J Med Sci; 2004 Mar; 20(3):124-7. PubMed ID: 15124896
[TBL] [Abstract][Full Text] [Related]
4. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M
Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752
[TBL] [Abstract][Full Text] [Related]
5. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of Th1 response in decoy receptor 3 transgenic mice.
Hsu TL; Wu YY; Chang YC; Yang CY; Lai MZ; Su WB; Hsieh SL
J Immunol; 2005 Oct; 175(8):5135-45. PubMed ID: 16210617
[TBL] [Abstract][Full Text] [Related]
7. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.
Arakawa Y; Tachibana O; Hasegawa M; Miyamori T; Yamashita J; Hayashi Y
Acta Neuropathol; 2005 Mar; 109(3):294-8. PubMed ID: 15627206
[TBL] [Abstract][Full Text] [Related]
8. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
10. Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen.
Matute-Bello G; Liles WC; Frevert CW; Dhanireddy S; Ballman K; Wong V; Green RR; Song HY; Witcher DR; Jakubowski JA; Martin TR
J Infect Dis; 2005 Feb; 191(4):596-606. PubMed ID: 15655784
[TBL] [Abstract][Full Text] [Related]
11. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE
Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095
[TBL] [Abstract][Full Text] [Related]
12. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis.
Roth W; Wagenknecht B; Klumpp A; Naumann U; Hahne M; Tschopp J; Weller M
Cell Death Differ; 2001 Apr; 8(4):403-10. PubMed ID: 11550092
[TBL] [Abstract][Full Text] [Related]
13. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.
Pitti RM; Marsters SA; Lawrence DA; Roy M; Kischkel FC; Dowd P; Huang A; Donahue CJ; Sherwood SW; Baldwin DT; Godowski PJ; Wood WI; Gurney AL; Hillan KJ; Cohen RL; Goddard AD; Botstein D; Ashkenazi A
Nature; 1998 Dec; 396(6712):699-703. PubMed ID: 9872321
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
15. Irradiation induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions.
Streffer JR; Schuster M; Pohl U; Belka C; Dichgans J; Bamberg M; Weller M
Anticancer Res; 1999; 19(6B):5265-9. PubMed ID: 10697547
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.
Shen HW; Gao SL; Wu YL; Peng SY
World J Gastroenterol; 2005 Oct; 11(38):5926-30. PubMed ID: 16273601
[TBL] [Abstract][Full Text] [Related]
17. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.
Shi G; Wu Y; Zhang J; Wu J
J Immunol; 2003 Oct; 171(7):3407-14. PubMed ID: 14500635
[TBL] [Abstract][Full Text] [Related]
18. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death.
Steinbach JP; Wolburg H; Klumpp A; Weller M
J Neurochem; 2005 Mar; 92(6):1340-9. PubMed ID: 15748153
[TBL] [Abstract][Full Text] [Related]
20. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
